Selected research
Industry Research
Finasteride Industry Research Report 2026
Market perspective
The global Finasteride market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Finasteride is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Finasteride is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Finasteride is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Finasteride include Teva Pharmaceuticals, Sandoz, Shandong Renhetang Pharmaceutical, Merck, Zhejiang CONBA Pharmaceutical, Henan Topfond, Guangdong Eashu Pharmacetical, RelonChem and Dr. Reddy, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Finasteride market in terms of revenue (US$ million) and, where applicable, sales volume (tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Finasteride Market by Company
Teva Pharmaceuticals
Sandoz
Shandong Renhetang Pharmaceutical
Merck
Zhejiang CONBA Pharmaceutical
Henan Topfond
Guangdong Eashu Pharmacetical
RelonChem
Dr. Reddy
Cipla
Actavis
Accord Pharmaceuticals
Finasteride Segment by Type
1mg Tablet
5mg Tablet
Finasteride Segment by Application
Medical Uses
Application 2
Finasteride Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Finasteride market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Finasteride and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Finasteride.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Finasteride manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Finasteride by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Finasteride in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 1mg Tablet
- 5mg Tablet
Applications
- Medical Uses
- Application 2
Companies covered
- Teva Pharmaceuticals
- Sandoz
- Shandong Renhetang Pharmaceutical
- Merck
- Zhejiang CONBA Pharmaceutical
- Henan Topfond
- Guangdong Eashu Pharmacetical
- RelonChem
- Dr. Reddy
- Cipla
- Actavis
- Accord Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Finasteride Market Size (2021-2032)
- 2.2.2 Global Finasteride Sales (2021-2032)
- 2.2.3 Global Finasteride Market Average Price (2021-2032)
- 2.3 Finasteride by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 1mg Tablet
- 2.3.3 5mg Tablet
- 2.4 Finasteride by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Medical Uses
- 2.4.3 Application 2
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Finasteride Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Finasteride Sales (tons) of Manufacturers (2021-2026)
- 3.3 Global Finasteride Revenue of Manufacturers (2021-2026)
- 3.4 Global Finasteride Average Price by Manufacturers (2021-2026)
- 3.5 Global Finasteride Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Finasteride, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Finasteride, Product Type & Application
- 3.8 Global Manufacturers of Finasteride, Established Date
- 3.9 Global Finasteride Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceuticals
- 4.1.1 Teva Pharmaceuticals Company Information
- 4.1.2 Teva Pharmaceuticals Business Overview
- 4.1.3 Teva Pharmaceuticals Finasteride Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceuticals Finasteride Product Portfolio
- 4.1.5 Teva Pharmaceuticals Recent Developments
- 4.2 Sandoz
- 4.2.1 Sandoz Company Information
- 4.2.2 Sandoz Business Overview
- 4.2.3 Sandoz Finasteride Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sandoz Finasteride Product Portfolio
- 4.2.5 Sandoz Recent Developments
- 4.3 Shandong Renhetang Pharmaceutical
- 4.3.1 Shandong Renhetang Pharmaceutical Company Information
- 4.3.2 Shandong Renhetang Pharmaceutical Business Overview
- 4.3.3 Shandong Renhetang Pharmaceutical Finasteride Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Shandong Renhetang Pharmaceutical Finasteride Product Portfolio
- 4.3.5 Shandong Renhetang Pharmaceutical Recent Developments
- 4.4 Merck
- 4.4.1 Merck Company Information
- 4.4.2 Merck Business Overview
- 4.4.3 Merck Finasteride Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Merck Finasteride Product Portfolio
- 4.4.5 Merck Recent Developments
- 4.5 Zhejiang CONBA Pharmaceutical
- 4.5.1 Zhejiang CONBA Pharmaceutical Company Information
- 4.5.2 Zhejiang CONBA Pharmaceutical Business Overview
- 4.5.3 Zhejiang CONBA Pharmaceutical Finasteride Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Zhejiang CONBA Pharmaceutical Finasteride Product Portfolio
- 4.5.5 Zhejiang CONBA Pharmaceutical Recent Developments
- 4.6 Henan Topfond
- 4.6.1 Henan Topfond Company Information
- 4.6.2 Henan Topfond Business Overview
- 4.6.3 Henan Topfond Finasteride Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Henan Topfond Finasteride Product Portfolio
- 4.6.5 Henan Topfond Recent Developments
- 4.7 Guangdong Eashu Pharmacetical
- 4.7.1 Guangdong Eashu Pharmacetical Company Information
- 4.7.2 Guangdong Eashu Pharmacetical Business Overview
- 4.7.3 Guangdong Eashu Pharmacetical Finasteride Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Guangdong Eashu Pharmacetical Finasteride Product Portfolio
- 4.7.5 Guangdong Eashu Pharmacetical Recent Developments
- 4.8 RelonChem
- 4.8.1 RelonChem Company Information
- 4.8.2 RelonChem Business Overview
- 4.8.3 RelonChem Finasteride Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 RelonChem Finasteride Product Portfolio
- 4.8.5 RelonChem Recent Developments
- 4.9 Dr. Reddy
- 4.9.1 Dr. Reddy Company Information
- 4.9.2 Dr. Reddy Business Overview
- 4.9.3 Dr. Reddy Finasteride Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Dr. Reddy Finasteride Product Portfolio
- 4.9.5 Dr. Reddy Recent Developments
- 4.10 Cipla
- 4.10.1 Cipla Company Information
- 4.10.2 Cipla Business Overview
- 4.10.3 Cipla Finasteride Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Cipla Finasteride Product Portfolio
- 4.10.5 Cipla Recent Developments
- 4.11 Actavis
- 4.11.1 Actavis Company Information
- 4.11.2 Actavis Business Overview
- 4.11.3 Actavis Finasteride Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Actavis Finasteride Product Portfolio
- 4.11.5 Actavis Recent Developments
- 4.12 Accord Pharmaceuticals
- 4.12.1 Accord Pharmaceuticals Company Information
- 4.12.2 Accord Pharmaceuticals Business Overview
- 4.12.3 Accord Pharmaceuticals Finasteride Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Accord Pharmaceuticals Finasteride Product Portfolio
- 4.12.5 Accord Pharmaceuticals Recent Developments
5 Global Finasteride Market Scenario by Region
- 5.1 Global Finasteride Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Finasteride Sales by Region: 2021-2032
- 5.2.1 Global Finasteride Sales by Region: 2021-2026
- 5.2.2 Global Finasteride Sales by Region: 2027-2032
- 5.3 Global Finasteride Revenue by Region: 2021-2032
- 5.3.1 Global Finasteride Revenue by Region: 2021-2026
- 5.3.2 Global Finasteride Revenue by Region: 2027-2032
- 5.4 North America Finasteride Market Facts & Figures by Country
- 5.4.1 North America Finasteride Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Finasteride Sales by Country (2021-2032)
- 5.4.3 North America Finasteride Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Finasteride Market Facts & Figures by Country
- 5.5.1 Europe Finasteride Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Finasteride Sales by Country (2021-2032)
- 5.5.3 Europe Finasteride Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Finasteride Market Facts & Figures by Country
- 5.6.1 Asia Pacific Finasteride Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Finasteride Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Finasteride Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Finasteride Market Facts & Figures by Country
- 5.7.1 South America Finasteride Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Finasteride Sales by Country (2021-2032)
- 5.7.3 South America Finasteride Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Finasteride Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Finasteride Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Finasteride Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Finasteride Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Finasteride Sales by Type (2021-2032)
- 6.1.1 Global Finasteride Sales by Type (2021-2032) & (tons)
- 6.1.2 Global Finasteride Sales Market Share by Type (2021-2032)
- 6.2 Global Finasteride Revenue by Type (2021-2032)
- 6.2.1 Global Finasteride Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Finasteride Revenue Market Share by Type (2021-2032)
- 6.3 Global Finasteride Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Finasteride Sales by Application (2021-2032)
- 7.1.1 Global Finasteride Sales by Application (2021-2032) & (tons)
- 7.1.2 Global Finasteride Sales Market Share by Application (2021-2032)
- 7.2 Global Finasteride Revenue by Application (2021-2032)
- 7.2.1 Global Finasteride Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Finasteride Revenue Market Share by Application (2021-2032)
- 7.3 Global Finasteride Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Finasteride Value Chain Analysis
- 8.1.1 Finasteride Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Finasteride Production Mode & Process
- 8.2 Finasteride Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Finasteride Distributors
- 8.2.3 Finasteride Customers
9 Global Finasteride Analyzing Market Dynamics
- 9.1 Finasteride Industry Trends
- 9.2 Finasteride Industry Drivers
- 9.3 Finasteride Industry Opportunities and Challenges
- 9.4 Finasteride Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst